NewLimit raises 435 million for life extension

NewLimit, a longevity startup, is preparing to begin its first clinical trial for a liver medicine after securing $435 million in new funding. The company revealed the details Tuesday, marking a major milestone in its efforts to develop treatments aimed at extending human lifespan.

The Series C round was led by Founders Fund, the Silicon Valley venture capital firm co-founded by Peter Thiel. Additional investors included Thrive Capital, Lilly Ventures, and tech entrepreneurs Nat Friedman and Daniel Gross. NewLimit’s valuation now stands at approximately $3.1 billion, according to co-founder and CEO Jacob Kimmel.

Founded in 2021, the company was launched by Brian Armstrong, co-founder and former CEO of Coinbase; Blake Byers, a former GV partner and bioengineer; and Kimmel, a stem cell biologist. It has accelerated its growth, securing multiple funding rounds in the past year alone.

Related: Woman behind world’s largest longevity competition

The startup previously raised $130 million in a Series B round in May 2025, followed by an additional $45 million in October. These earlier investments helped fund research into cellular aging and regenerative medicine, areas it now aims to translate into clinical applications.

Its focus on liver medicine represents a shift toward therapies that address organ-specific degeneration. The clinical trial will test a treatment designed to repair or regenerate liver tissue, a critical step in validating its approach to longevity.

Investors have shown sustained interest in the company’s vision, despite the high risks associated with longevity research. Its ability to attract top-tier venture capital firms suggests confidence in its scientific roadmap and potential market impact.

Related: 47 Complete Tips to Improve Your Health Insurance

While the clinical trial is a first for the company, it has already filed several patents related to its regenerative technologies. These filings, though not publicly detailed, indicate a focus on proprietary methods for targeting aging cells.

The funding will also support expansion of its research teams and infrastructure. It plans to open new labs in the coming months, though specific locations remain undisclosed. This growth aligns with its goal of advancing multiple therapies simultaneously.

Longevity research remains a niche but rapidly growing sector. Its valuation places it among the most well-funded startups in the field, though its clinical progress will determine whether it can sustain investor interest over time.

Related: Revolution Medicines ships experimental pancreatic cancer drug

Experts outside the company note that the field faces significant challenges, including regulatory hurdles and the difficulty of proving long-term benefits in human trials. Its trial will be closely watched as a test case for the broader industry.

The startup’s founders have not yet commented publicly on the trial’s design or expected timelines. However, the funding round signals a willingness by investors to support ambitious projects despite the high failure rates common in biotech innovation.

With its latest capital, it is positioning itself to bridge the gap between laboratory discoveries and real-world medical applications. The outcome of its first trial could shape the future of longevity science for years to come.